KEYNOTE-365 cohort B: Pembrolizumab (pembro) plus docetaxel and   prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated   patients with metastatic castration-resistant prostate cancer   (mCRPC)-New data after an additional 1 year of follow-up.

Document type:: Meeting Abstract
Author(s):: Appleman, Leonard Joseph; Kolinsky, Michael Paul; Berry, William R.; Retz, Margitta; Mourey, Loic; Piulats, Josep M.; Romano, Emanuela; Gravis, Gwenaelle; Gurney, Howard; De Bono, Johann S.; Boegemann, Martin; Emmenegger, Urban; Joshua, Anthony M.; Massard, Christophe; Sridhar, Srikala S.; Conter, Henry Jacob; Li Xin Tong, XT; Schloss, Charles; Poehlein, Christian Heinrich; Yu, Evan Y.
Title:: KEYNOTE-365 cohort B: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)-New data after an additional 1 year of follow-up.
Journal title abbreviation:: J Clin Oncol
Year:: 2021
Journal volume:: 39 Suppl S
Journal issue:: 6
Fulltext / DOI:: doi:10.1200/JCO.2021.39.6_suppl.10
Print-ISSN:: 0732-183X
TUM Institution:: Urologische Klinik und Poliklinik
BibTeX

Occurrences: